



New Trends in Management of Non-Muscle Invasive Bladder Cancer

Essay Submitted For Partial Fulfillment of the Requirement
of
Master Degree in Urology

Submitted By

NADER FATHY THABET

MB. Bch Ain-Shams University

Under Supervision of

Prof. Dr. SHEREEN RAGY

Professor of Urology, Faculty of Medicine
Ain-Shams University

&

Prof. Dr. KHALED TEAMA

Professor of Urology, Faculty of Medicine
Ain-Shams University

2010

ACKNOWLEDGMENT

*I am greatly honored to express my greatest gratitude & thanks to **Prof. Dr. Shereen Ragy**, Professor of Urology, Faculty of Medicine, Ain-Shams University for undertaking the main supervision of this thesis. His precious advice, gentle guidance & kind support throughout the entire work, which were of unlimited value.*

*I would like to express my deepest sincere thanks to **Prof. Dr. Khaled Teama**, Professor of Urology, Faculty of Medicine, Ain-Shams University for his very great valuable help, generosity & unlimited support in every detail of this work.*

Special thanks, admiration & respect to all the staff members & residents of the Urology department Ain-Shams Medical School for their kind help, guidance & support.

My deepest thanks & respect to Dr. Mohamed Abd El Fatah for his full help, dedication, support & generosity that helped me along my whole way.

Nader Fathy

***This Thesis is dedicated to the soul of my father,
my Mother and my sisters with all my love and
admiration.***

Table of Contents

		Page
	Introduction	X
	Aim Of The Study	XIII
<i>Chapter 1 Epidemiology of NMIBC</i>		
1	Incidence & Prevalence: Sex & Race	2
2	Age	4
3	Regional & National Differences	6
<i>Chapter 2 Etiology And Risk Factors</i>		
1	Basic Biology	9
2	Oncogenes	9
3	Tumor Suppressor Genes	10
<i>Chapter 3 Histology & Histopathology</i>		
1	Normal Bladder Urothelium	14
2	Epithelial Hyperplasia & Metaplasia	15
3	Urothelial Dysplasia	16
	a) Preneoplastic Proliferative Abnormalities	16
	b) Dysplasia	16
	c) Nephrogenic Adenoma	17
	d) Pseudosarcoma (Postoperative Spindle Cell Nodule)	18



4	Carcinoma In Situ	18
5	Transitional Cell (Urothelial) Carcinoma	20
	• Tumor Architecture	20
	• Tumor Grading	22
	➤ Well-Differentiated Tumors	24
	➤ Moderately Differentiated	25
	➤ Poorly Differentiated Tumors	26
	• Pathologic Staging	29
	• Tumor Staging	31
	• Superficial Versus Infiltrating Tumor	32

Chapter 4 Prognostic Indicators

1	Clinical & Pathologic Parameters In Non-Muscle-Invasive Bladder Cancer (NMIBC).....	36
2	The EORTC risk tables for predicting recurrence and progression in individual patients.....	40
3	EORTC risk tables for Stage Ta T1 Bladder Cancer ..	43
4	Tumor Stage & Progression	44
5	Tumor Grade & Its Prognostic Significance	45
6	Carcinoma In Situ & Its Prognostic Value	47

Chapter 5 Diagnosis & Investigations

1	Symptoms & Signs	50
2	Imaging	51
3	Urine Cytology.....	52
4	Cystoscopy	52
5	Transurethral Resection Of TaT1 Bladder Tumors	53
6	Bladder Biopsies	53



7	Flow Cytometry	54
8	Image Analysis	54
9	Excretory Urography	55

Chapter 6 Treatment Of NMIBC

1	Treatment Of NMIBC According To EORTC Risk Tables	57
	A. Low-Risk Tumors	60
	B. High-Risk Tumors	65
	C. Intermediate-Risk Tumors	71
	• Conventional Treatment	71
	• Gemcitabine	75
	• Device Assisted Therapies	76
2	Intravesical Chemotherapy	78
	A. Mitomycin C	79
	B. Doxorubicin & Its Derivatives	81
	C. Thiotepa	82
	D. Novel Agents	83
	E. Combination Therapy	84
3	Immunotherapy	85
	• Bacillus Calmette-Guérin	86
	• BCG Treatment of Carcinoma in Situ (CIS)	88
	• BCG Treatment of Residual Tumor	89
	• BCG Prophylaxis to Prevent Recurrence	90
	• Impact of BCG on Progression	91
	• Determining Optimum BCG Treatment Schedule	93



• Recommendations for Treatment of NMIBC	96
• Recommendations for Low Risk Tumors	96
• Recommendations for Intermediate Risk Tumors	96
• Recommendations for High Risk Tumors	97

<i>English Summary</i>	99
------------------------------	----

<i>References</i>	102
-------------------------	-----

<i>Arabic Summary</i>	123
-----------------------------	-----

List of tables

Table 1	:	The WHO 1973 grading system	22
Table 2	:	The WHO 2004 grading system	28
Table 3	:	TNM Staging of cancer bladder	33
Table 4	:	Scoring system of prognostic factors for non muscle invasive bladder	39
Table 5	:	EORTC Risk Tables for Stage Ta T1 Bladder Cancer	43



List of figures

Fig 1	: Normal Bladder Urothelium	14
Fig 2	: Carcinoma in Situ	19
Fig 3	: Grading system for urothelial bladder tumors	23
Fig 4	: Well Differentiated Transitional Cell Carcinoma	25
Fig 5	: Moderately Differentiated Transitional Cell Carcinoma	26
Fig 6	: Undifferentiated Transitional Cell Carcinoma	27
Fig 7	: Tumor Staging	31

List of Abbreviations (In Alphabetic Order)

A

AUA : American Urological Association

B

BCG : Bacillus Calmette-Guérin

C

CIS : Carcinoma In Situ

E

EMDA : Electromotive drug administration

EORTC : The European Organization for Research & Treatment of Cancer

F

FDA : Food & Drug Administration

I

IFN	:	Interferon
IL	:	Interleukin
ISUP	:	The International Society of Urological Pathology
IP	:	Intraocular Pressure

K

KD	:	Kilo Dalton
-----------	---	-------------

M

MMC	:	Mitomycin C
------------	---	-------------

N

NMIBC	:	Non-Muscle-Invasive Bladder Cancer
--------------	---	------------------------------------

P

PDT	:	Photodynamic Therapy
PUNLMP	:	Papillary Urothelial Neoplasms of Low Malignant Potential

S

SWOG : Southwest Oncology Group

T

TCC : Transitional Cell Carcinoma

TUR : Transurethral Resection

TURBT : Transurethral Resection Of The Bladder Tumor

TURP : Transurethral Resection Prostate

U

UCC : Urothelial Cell Carcinoma

W

WHO : The World Health Organization

5-ALA : Aminolevulinic Acid